GOT2 and neoplasm: Considering this context, we argue that GOT2 is likely to play distinct roles at different stages of T-cell exhaustion and might potentially be modulated by the spectrum of changes in TME conditions of KIRC patients, including tumor metabolism, hypoxia, nutrient restriction, and exhaustion driven by chronic stimulation, thus strengthening the potential application of synergic modulation of the GOT2 and T cell exhaustion markers in non-responsive KIRC patients to boost antitumor and immune responses.